Solid Tumor/Phase I Clinical Trials

Showing 31-44 of 44 items
31.
32.
  • Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
  • This study will assess the efficacy and safety of MK-3475 administered to participants with advanced biomarker-positive solid tumors that have not responded to current therapy, for which current therapy is not appropriate, or for which no current therapy exists. The hypothesis is that administration of MK-3475 to participants with some types of solid tumors will result in a clinically meaningful response rate.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
33.
  • Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
  • This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1125976. The relative bioavailability of liquid service formulation and tablets will be determined. After the MTD is defined breast cancer patients with and without AKT1 mutation will be treated. The study will also assess the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of BAY1125976. BAY1125976 will be given daily as single oral application. Treatment will be stopped if the tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the patient decides to exit treatment.
  • Diagnoses: Breast: Metastatic, Solid Tumor/Phase I
  • Status: Recruiting
34.
35.
  • A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
  • This open-label, multicenter, Phase I, dose-escalation study will evaluate the s afety, tolerability and pharmacokinetics of GDC-0575 administered alone or in co mbination with gemcitabine in patients with refractory solid tumors or lymphoma. In Stage I, cohorts of patients will receive multiple ascending oral doses of G DC-0575 alone (Arm 1) or in combination with intravenous gemcitabine (Arm 2). In Stage II, patients will receive GDC-0575 orally in combination with intravenous gemcitabine at or below the maximum tolerated dose determined in Stage I. Antic ipated time on study treatment is until disease progression or unacceptable toxi city occurs, for a maximum of 17 cycles (approximately 1 year).
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
36.
37.
38.
39.
  • Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
  • The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the MTD. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
40.
41.
42.
43.
  • A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors
  • This is a first-in-human, Phase I, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in patients with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate. The planned duration of the study is approximately 3 years.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
44.
  • A Phase 1/2 Study to Evaluate MEDI4736
  • This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors. An exploration cohort has been added to determine the safety using Q4W dosing.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
Showing 31-44 of 44 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms